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Background: In the majority of cases, trigeminal neuralgia (TN) is a unilateral condition with ultra-short stabbing pain
located along one or more branches of the trigeminal nerve. Although prophylactic pharmacological treatment is first
choise, considering of insufficient effect or unacceptable side effects, neurosurgical treatment or lesion treatment
should be considered. In addition to all these procedures mentioned above, one approach has been based on local
intradermal and/or submucosal injections of Botulinum Toxin Type A (BTX-A).
Methods: We conducted a randomized, double-blind, placebo-controlled since November 2012, and adopted local
multi-point injection in 84 cases of classical TN with different doses of BTX-A. Eighty four patients were randomized into
following groups: placebo (n = 28); BTX-A 25U (n = 27); BTX-A 75U (n = 29). Follow-up visits were conducted every week
after the injection, and the overall duration of the study for each patient were 8 weeks to observe the pain severity,
efficacy and adverse reactions at endpoint.
Results: The visual analogue scale (VAS) scores of 25U and 75U groups reduced significantly compared to placebo as
early as week 1, and sustained until week 8 throughout the study. There was no significant difference in VAS between
25U and 75U groups throughout the study. The response rates of 25U group (70.4%) and 75U group (86.2%) were
significantly higher than placebo group (32.1%) at week 8, and there was no significant difference between 25U and
75U groups. Evaluation of the Patient Global Impression of Change (PGIC) demonstrated that 66.7% (25U group) and
75.9% (75U group) of the patients reported that their pain symptoms were ‘much improved’ or ‘very much improved’
versus 32.1% of the placebo group, and there was also no significant difference between 25U and 75U groups. All
adverse reactions were graded as mild or moderate.
Conclusions: BTX-A injection in TN is safe and efficient. It is a useful treatment for refractory TN. Lower dose (25U) and
high dose (75U) were similar in efficacy in short-term.
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In the majority of cases, trigeminal neuralgia (TN) is a
unilateral condition with ultra-short stabbing pain located
along one or more branches of the trigeminal nerve. The
pain is often triggered by stimuli such as chewing, washing
of the face, speech and tooth-brushing [1]. It usually af-
fects one side of the face, and occurs more often in the
elderly and has a profound effect on quality of life. Ac-
cording to epidemiological studies, approximately 4–28.9/
100,000 persons worldwide experience TN [2-4].
Trigeminal neuralgia is primarily caused by compres-
sion of the nerve near its origin at the pons. The treat-
ment consists primarily of prophylactic pharmacological
treatment with anti-epileptics. In case of insufficient ef-
fect or unacceptable side effects, neurosurgical treatment
using microvascular decompression or lesion treatment
should be considered [5]. In addition to all these proce-
dures mentioned above, one approach has been based
on local intradermal and/or submucosal injections of
Botulinum Toxin Type A (BTX-A) [6].
BTX-A is one of the most potent neurotoxins from
natural toxins and synthetic toxicant known, which
blocks neuromuscular transmission through decreased
acetylcholine release, resulting in muscle relaxation. It is
also used in treating blepharospam and hemifacial spasm
[7]. Additionally it is reported to be effective in the treat-
ment of chronic migraine and may be a promising
choice in headache treatment [8-11]. In some reports,
BTX-A has been shown to be a new possible choice of
treatment for TN, and may be an efficient, safe and
novel strategy for TN treatment [6,12-19]. This therapy
is simple and can be performed as an outpatient proced-
ure without anesthesia, and the toxin does not cause
skin sensory loss or dysesthesia. However, there is no
large randomized controlled trial and relevant data ex-
cept our study in 2012 [6], and the dose has not been
standardised. The aim of the present study was to define
an effective and safe dose of BTX-A for the treatment.
For this purpose, we conducted a randomized, double-
blind, placebo-controlled since November 2012, and
adopted local multi-point injection in 84 cases of clas-
sical TN with different doses of BTX-A. The primary ob-
jective was to further clarify the efficacy, safety and
tolerability of intradermal and/or submucosal adminis-
tration of different doses of BTX-A in patients with TN.
Methods
Study design
The study was a randomized, double-blind, placebo-
controlled and parallel-group clinical study of BTX-A in
the management of patients with TN. The overall dur-
ation of the study for each patient was 9 weeks, includ-
ing a 1-week observation period to establish baseline
pain symptoms, followed by a 8-week placebo run-inperiod. Follow-up visits were conducted every week after
the injection.
The trial was approved by the local ethics committee
of the First Affiliated Hospital of Zhengzhou University.
The goal, procedure and possible adverse reactions of
the study were explained to each patient before the
study, and they were informed of the possibility of tran-
sient attendant risk of weakness and disfigurement pro-
duced by localized administration of BTX-A. Written
informed consent was obtained from each patient. Pa-
tients were free to discontinue the trial at any time dur-
ing the double-blind period.
The Patients were randomized into 3 groups: placebo
groups received sterile isotonic saline injection and treat-
ment group received 25U/1 mL (25U group) and 75U/
1 mL (75U group) of BTX-A in the dermatome and/or mu-
cosa (if the oral mucosa was involved) where pain was
experienced. Patients were assigned to a computer-gene
rated randomisation list, and randomization data were kept
strictly confidential, accessible only by authorized persons.
The data was locked and verified and unblended only when
the trial was completed.
Study participants
All included patients were recruited from the outpa-
tients and inpatients who attended the neurology depart-
ment of the First Affiliated Hospital of Zhengzhou
University from Nov 2012 to Aug 2013. Each patient
underwent MRI or CT to rule out the presence of struc-
tural pathology. All patients underwent detailed physical
examination and data registration, including the history
of present illness, past history, the auxiliary examination
results, nervous system examination. Complete blood
count (CBC), ECG, Liver function tests, renal function
tests and other diagnostic tests should be done before
the trial, to exclude coagulopathy, severe heart, liver, kid-
ney and other organ dysfunction. According to the
current version of the International Classification of
Headache Disorders (ICHD-II) [20], and all patients
were diagnosed with classical TN.
At baseline, patients usually received medications (e.g.
carbamazepine, gabapentin, or opioids) to alleviate their
pain. These medications remained unchanged during the
course of the study. There were no new analgesic therapies
at any time during the baseline or placebo run-in period.
Participants(>18 years), who were failure of recent treat-
ment for TN at baseline (pain intensity mean score ≥ 4;
mean attack frequency ≥ 4 per day; course > 4 months),
were required to be in good general health, and under-
standing the possible complications such as transient fa-
cial weakness.
Exclusion criteria included: any disease that might put
patients at increased risk if exposed to BTX-A (e.g. my-
asthenia gravis, motor neuron disease or Lambert-Eaton
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jection sites; use of drug that damage the neuromuscular
junction within 7 days before study entry (e.g. quinine,
aminoglycosides or penicillamine); significant unstable
medical disease or a history of a significant mental dis-
order; history of substance dependence or abuse. Further-
more, women who were pregnant, nursing, or planning a
pregnancy during the study, or who were unable or un-
willing to use a reliable form of contraception during the
study were also excluded.
Patients who continued to meet all inclusion/exclusion
criteria at the end of the baseline phase were random-
ized and proceeded to the double-blind period.Treatment
All of the treatment was administered in the treatment
room at the Department of Neurology, the First Affiliated
Hospital of Zhengzhou University, which is equipped with
all the necessary facilities to ensure the safety of possible
severe reactions or emergencies.
BTX-A (100U of Clostridium botulinum type A neuro-
toxin complex, 5 mg gelatin, 25 mg dextran, and 25 mg
saccharose) was obtained from Lanzhou Biological Prod-
ucts Institute, China. Patients lay still in a supine position
on a bed during the injections.
Patients were randomly assigned to receive treatment
with placebo or total doses of 25Uor 75U of botulinum
toxin type A (placebo group, 25U group, or 75U group)
in a double blind prospective study design. The way to
blind the study was to supply the study medication for
each patient in three individual vials. Each vial contained
either active botulinum toxin type A (25U or 75U) or
matching placebo. All three vials were identical in appear-
ance and were reconstituted with 1 ml saline solution
(0.9%). For treatment 1 ml was drawn from vials, and the
injections were administered intradermally and/or submu-
cosally using a 1 mL syringe with a 0.45 × 16 mm needle.
The BTX-A or the same volume of isotonic saline
were applied at 20 points, (0.05 ml) per point, between
the epidermis and dermis of the skin where pain was ex-
perienced according to the patient’s description. The in-
jections were conducted submucosally in the oral
mucosa if the pain involved the oral mucosa. During the
procedure, injection in deeper structures such as the
muscles was avoided to prevent unwanted effects.Efficacy and safety measures
On awakening each morning, patients were required to
provide a verifiable diary of their pain symptoms cover-
ing provoking factors, frequency of TN attacks, severity
of pain (according to an 11-point visual analogue scale,
VAS) and adverse reaction experienced during the previ-
ous 24 hours from baseline to endpoint. During thebaseline phase, patient demographics, gender, and age
were also recorded.
The following items were assessed during each follow
up visit:
 Assessment of pain severity and pain attack
frequency from baseline to endpoint.
 Global assessment of the overall response to
treatment on the basis of the Patient Global
Impression of Change (PGIC) scale. The PGIC is a
self-evaluation of the patient’s overall change since
the start of the study according to a seven-point
scale (1, very much improved; 2, much improved; 3,
minimally improved; 4, no change; 5, minimally
worse; 6, much worse; 7, very much worse).
 The proportion of responders, defined as patient
with ≥ 50% reduction in mean pain score from
baseline to endpoint, was also used to assess the
efficacy of the treatment.
 Safety was measured as the occurrence of adverse
events and recorded with information including the
date of onset, severity, duration, frequency,
treatment required (if any), relationship to BTX-A
treatment, and outcome.Statistical analysis
All analyses were performed on the intent-to-treat popu-
lation and all statistical testing was two-sided. The quan-
titative data was assessed using the median value.
Between groups comparisons were evaluated by means
of the Kruskall-Wallis analysis to compare the age, dur-
ation of diseases, and pain intensity. Chi-square test was
performed to assess the differences of the gender, PGIC
distribution, and the proportion of responders among 3
groups. The SPSS 20.0 software package was used for
statistical evaluation; p < 0.05 was considered statistically
significant.Results
Patient disposition
The recruitment period was between November 2012
and August 2013, with an 8-week follow-up period after
the last patient was enrolled. A total of 95 patients were
screened, and 84 were randomized into the following
groups: placebo (n = 28); BTX-A 25U (n = 27); BTX-A
75U (n = 29). Four patients (one from 25U group, one
from 75U group and two from placebo group) withdrew
from the study owing to a lack of efficacy, leaving data
on 80 patients for the final analysis. Overall, the groups
were well matched for age, sex, duration of symptoms,
pain severity, and pain attack frequency, and there were
no significant differences at baseline (Table 1).
Table 1 Demographic characteristics and details at baseline
Characteristics Placebo (n = 27) BTX-A (25u) (n = 25) BTX-A (75u) (n = 28) Total (n = 80) P value
Age, mean (SD), y Mean (SD) 58.41 (11.74) 58.16 (11.54) 62.64 (13.32) 59.81 (12.30) 0.363
Median 60 59 63 60
Min/max 31/78 41/80 40/89 31/89
Mean months since onset of TN Mean (SD) 50.96 (46.26) 91.96 (72.61) 72.64 (76.45) 71.36 (67.68) 0.181
Median 36 96 36 48
Min/max 4/210 4/300 4/270 4/300
Sex Male 51.85% 40% 42.86% 45% 0.665
Pain intensity,VAS Mean (SD) 6.96 (1.97) 6.24 (2.13) 7.18 (2.21) 6.81 (2.12) 0.197
Median 7 5 6.5 6
Min/max 4/10 4/10 4/10 4/10
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At baseline, each group was well matched for severity of
their VAS scores (6.96 ± 1.97, 6.24 ± 2.13, and 7.18 ± 2.21
for placebo, 25U, and 75U groups respectively). After in-
jections, The VAS scores of 25U and 75U groups re-
duced significantly compared to placebo as early as
week 1, and sustained until week 8 throughout the
study (*P < 0.017, **P < 0.017) (Figure 1). There was no
significant difference between 25U and 75U groups
throughout the study (P > 0.05) (Figure 1, Table 2).
Efficacy results
The proportion of responders, defined as patient with ≥
50% reduction in mean pain score from baseline to end-
point, was used to assess the efficacy. The response rates
of 25U group (70.4%) and 75U group (86.2%) were sig-
nificantly higher than placebo group (32.1%) at week 8Figure 1 Weekly mean scores as measured by VAS. At baseline,
each group was well matched for severity of their VAS scores. After
injections, The VAS scores of 25U and 75U groups reduced significantly
compared to placebo as early as week 1, and sustained until week 8
throughout the study (*P < 0.017, **P < 0.017) . There was no
significant difference between 25U and 75U groups throughout the
study (P > 0.05).(*P < 0.017). There was no significant difference between
25U and 75U groups (P > 0.05) (Figure 2).
Evaluation of the PGIC demonstrated that 66. 7% of the
patients in 25U group reported that their pain symptoms
were ‘much improved’ or ‘very much improved’ versus
32.1% of the placebo group (*P < 0.017). In addition, there
was a much higher proportion in 75U group (*P < 0.017)
(75.9%), but there was no significant difference between
25U and 75U groups (P > 0.05) (Figure 3).Safety and adverse reaction
Three patients (two in 25U group, one in 75U group)
experienced short term facial asymmetry in the injection
area during dynamic movement, which disappeared
within 6 weeks. Transient edema in the injection area
was observed in two patients (both in 25U group), and
disappeared within 5 days. All adverse reactions were
graded as mild or moderate, and none led to discontinu-
ation of study.Discussion and conclusions
The International Association for the Study of Pain de-
fines trigeminal neuralgia (TN) as “sudden, usually uni-
lateral, severe, brief, stabbing, recurrent episodes of pain
in the distribution of one or more branches of the tri-
geminal nerve”. Medical management is the first choice,
including Carbamazepine, Oxcarbazepine, Bacloten, Lamo-
trigine, Gabapentin and ropivacaine. When drug treat-
ments fail due to pharmacoresistance or intolerability of
side effects, surgical treatments need to be considered. Sur-
gical treatments include peripheral techniques (such as
cryosurgery, neurectomy, laser, acupuncture, thermocoagu-
lation, injections of streptomycin, alcohol and phenol),
Gasserian ganglion radiofrequency thermocoagulation, gly-
cerol, balloon compression, Gamma knife and microvascu-
lar decompression. All the surgical treatments can result in
nerve damage except microvascular decompression, which
limits the application of these techniques. We faced with








1 −3.696 6.307 -.586 0.558
2 -.229 6.303 -.036 0.971
3 −1.258 6.255 -.201 0.841
4 2.709 6.208 0.436 0.663
5 5.166 6.205 0.833 0.405
6 2.099 6.200 0.339 0.735
7 2.588 6.211 0.417 0.677
8 3.784 6.230 0.607 0.544
Kruskall-Wallis test.
There was no significant difference between 25U and 75U groups throughout
the study in the visual analogue scale (VAS) scores.
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surgical treatment.
In 2002, analgesic effect of BTX-A in TN was reported
[14]. Some open studies [17] and a randomized con-
trolled trial (RCT) [6] showed that BTX-A could signifi-
cantly relieve pain in TN. The subcutaneously injection
usually was adopted in many points[9,21],or muscle in-
jection in region of the zygomatic arch [18] or in mas-
seter [19]. But the dose has not been standardised. Based
on our previous experience, the highest dose is 170U in
a woman with the third branch injection, and the pain
was completely relieved for 2 years [6,13]. In the present
study, the VAS scale between 25U and 75U group were
no significant difference from the first week to eighth
week. However, the high dose led to facial weakness with
high risk in our study.
Pain relief was observed in several minutes after injec-
tion [7], usually several days or as long as 20 days afterFigure 2 The proportion of responders. The response rates of
25U group (70.4%) and 75U group (86.2%) were significantly higher
than placebo group (32.1%) at week 8 (*P < 0.017). There was no
significant difference between 25U and 75U groups (P > 0.05).injection [13]. In this study, the VAS scale was different
between BTX-A and control group in the first week. The
pain was relieved rapidly. The effect of BTX-A on TN
usually lasted for several months [18,22]. Based on our
previous experience, it may last for from 8 weeks to
2 years, but it was still unknown whether effect duration
was associated with dose [6,13]. It was felt that the dur-
ation of pain relief sometimes was longer than the
period of muscle weakness in our study. Because of this,
it was considered that the antinociceptive effect of BTX-
A may not associate with inhibiting the release of acetyl-
choline from the neuromuscular junction.
More patients in 25U and 75U group presented that
they were “much improved” or “very much improved”
than control in PGIC, but it was similar between 25U
and 75U group at the endpoint. The effective rate was
not significant different between 25U and 75U group,
but they were different with control group. Complica-
tions induced by BTX-A were mild, including regional
weakness, facial asymmetry during voluntary movement
and edema in injection sites. Regional weakness and
edema were transient and usually recovered within sev-
eral weeks, and there were no systemic complications.
Recent studies showed that BTX-A may reduce neuro-
genic inflammation by inhibiting the release of glutam-
ate, substance P and calcitonin gene-related peptide
(CGRP) in sensory terminal [23]. BTX-A may also re-
duce the release of substance P in dorsal root ganglia
[24]. In other animal studies, BTX-A inhibits CGRP re-
lease in trigeminal sensory neurons of brainstem [25].
Diminishing peripheral sensory nerve chemical stimuli
may contribute to decreased peripheral and central ner-
vous system responsiveness [26]. More research is
needed to explore the mechanism of action of BTX-A
on pain in TN. BTX-A or its degradation product could
achieve analgesic effect through indirect effects on spinalFigure 3 Patient Global Impression of Change (PGIC) results.
Evaluation of the PGIC demonstrated that 66.7% of the patients in
25U group reported that their pain symptoms were ‘much
improved’ or ‘very much improved’ versus 32.1% of the placebo
group (*P < 0.017). In addition, there was a much higher proportion
in 75U group (75.9%) compare to the placebo group (*P < 0.017),
but there was no significant difference between 25U and 75U
groups (P > 0.05).
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vous system or diminishing the inhibition of inhibitory
interneuron renshaw cell [27]. Other Study of BTX-A
treatment of migraine indicated that the analgesic effect of
BTX-A not only associated with inhibiting the release of
acetylcholine, but also associated with blocking the para-
sympathetic nervous system [28].
Taken together, our study suggested that BTX-A injec-
tion in TN was safe and efficient. It is a useful treatment
for refractory TN. Lower dose (25U) and high dose
(75U) were similar in efficacy in short-term. But we can-
not claim that they were same in the long term. More
studies are needed to clarify it in the following study.
Research highlights
1. BTX-A injection in TN is safe and efficient.
2. BTX-A is a useful treatment for refractory TN.
3. Lower dose (25U) and high dose (75U) were similar
in efficacy in short-term.
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